title: NF-kappaB and STAT3 signaling in glioma: targets for future therapies.
abstract: Glioblastoma remains the most clinically challenging tumor of the CNS, as evidenced by the dismal change in overall survival over the past 50 years. However, recent advances in high-throughput screening techniques have given rise to a wealth of new information regarding the aberrant signaling pathways that drive the tumor phenotype. Two of these so-called 'oncopathways' are NF-kappaB and JAK/STAT. This review will describe the basic mechanisms of these pathways, explore the relevance of NF-kappaB and JAK/STAT signaling in glioblastoma, and look ahead to experimental compounds that will integrate our knowledge of these pathways into existing therapies.
authors.affiliation: Department of Cell Biology, University of Alabama at Birmingham, Birmingham, AL 35294-0005, USA.
authors.forename: George P
authors.initials: GP
authors.lastname: Atkinson
authors.forename: Susan E
authors.initials: SE
authors.lastname: Nozell
authors.forename: Etty Tika N
authors.initials: ET
authors.lastname: Benveniste
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D005910:Glioma / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D006801:Humans; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism*; D050796:STAT3 Transcription Factor / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction / Q000502:physiology*
chemical_list: D000970:Antineoplastic Agents; D016328:NF-kappa B; D050796:STAT3 Transcription Factor